AFL

Analyst Note: AFL (Aflac Incorporated)

Date: 2026-06-13 Event Date: 2026-06-13

1. Structural Readiness

• Conservative Entry: $117.47
• Current Price: $115.47
• Extension: -1.7% vs. conservative entry (Price is currently below the breakout trigger).
• Breakout Level: $117.47 (Conservative).

Volatility Context:

• ATR at Breakout: 2.0% (Sub-threshold).
• Current ATR: 1.9% (Sub-threshold).
• Assessment: Both metrics fall below the 2.5% structural quality threshold. This indicates lower volatility and a "tighter" structure, which may suggest a slower, more deliberate move rather than a high-velocity expansion.

2. Thesis Layer

Thesis Classification: Tactical / Setup-Led Secular Thesis: None named at this date.

3. Business Overview

Company: Aflac Incorporated Industry: Healthcare / Insurance (Supplemental Health and Life) Segments: Aflac Japan and Aflac U.S.

Business Model: Aflac operates as a supplemental health and life insurance provider, focusing on delivering value to customers in Japan and the U.S. The company generates revenue through premiums and investment income, with a specific focus on products that fill gaps in national healthcare systems.

Key Business Drivers (as of Q1 2026):

• Aflac Japan: The principal contributor to consolidated earnings. The segment is the largest insurer in Japan for cancer and medical (third sector) insurance.
• Sales Growth: Q1 2026 sales increased by 25.5% year-over-year.
• Product Mix: Growth was driven by new products, specifically "Onsen Tallett" (medical) and "Miraito" (cancer insurance).
• Profitability: Japan's total benefit ratio improved to 62.9% (down 290 bps YoY), and the pretax margin reached 35% (up 320 bps YoY).
• Strategic Moves: Effective March 31, 2026, Aflac Re Bermuda assumed a block of whole life annuities from Japan Post Insurance.
• Distribution: As of December 31, 2025, the company had agreements with approximately 90% of total banks in Japan.
• Aflac U.S.:
• Sales Growth: Q1 2026 sales increased by 2.9% year-over-year.
• Momentum: Management noted momentum in group voluntary products.
• Workforce: The U.S. sales force averaged approximately 5,300 active agents in 2025.
• Financial Performance:
• Net Earnings: $1.0 billion ($1.98 per diluted share) for Q1 2026, a significant recovery from $29 million ($0.05 per share) in Q1 2025.
• Adjusted Earnings: $901 million ($1.75 per share) for Q1 2026, compared to $906 million ($1.66 per share) in Q1 2025.
• Persistency: Net earned premium persistency remains strong at 79.3%.
• Capital Return: In Q1 2026, the company returned $1.3 billion to shareholders via share repurchases and dividends.
• Repurchase Capacity: As of March 31, 2026, 105.3 million shares remained authorized for repurchase.

Macro Context (Management View): Management notes that changes in Japan's economy and an aging population are shifting costs to consumers, creating demand for supplemental products. In the U.S., increased financial exposure for employees is viewed as a favorable opportunity for group voluntary products.

4. Archetype and Conviction

Archetype: Quality Compounder Rationale: The company fits the Quality Compounder archetype based on its consistent earnings recovery, strong margin expansion in Japan, and disciplined capital allocation.

• Margin Inflector: The 320 bps expansion in Japan's pretax margin (to 35%) and the 290 bps improvement in the benefit ratio demonstrate a clear inflection in operational efficiency.
• Capital Allocation: The return of $1.3 billion in a single quarter and the remaining authorization of 105.3 million shares indicate a commitment to shareholder value.
• Valuation Context: The financial spine indicates a forward consensus EPS of $7.06 for FY1 and $7.60 for FY2.

Conviction Stack:

• Thesis Strength: Low (Tactical only; no macro thesis).
• Evidence Quality: High. The earnings transcript and SEC filings provide robust, specific data points on sales growth, margins, and capital returns.
• Setup Readiness: Partial. The coil is forming but has not broken out. The price is currently -1.7% from the entry.
• Rerating Potential: Moderate. The strong earnings beat (Net earnings vs. prior year) and margin expansion provide fundamental support for a rerating, contingent on the price action confirming the setup.

5. Invalidations, Strengtheners, and Gaps

Invalidation:

• Fundamental Deterioration: A significant reversal in Japan's benefit ratio or a sharp decline in persistency rates would undermine the "Quality Compounder" thesis.

Strengtheners:

• Price Action: A close above $117.47 would confirm the breakout, moving the coil to "Confirmed Active."
• Fundamental: Continued sales growth in the U.S. segment or further margin expansion in Japan would reinforce the earnings trajectory.

Gaps in Evidence:

• Full Year Guidance: While Q1 2026 results are strong, specific full-year 2026 guidance or updated FY2027 expectations were not explicitly detailed in the provided evidence block beyond the consensus EPS.
• Interest Rate Sensitivity: The evidence does not explicitly quantify the impact of the current interest rate environment on the investment income portion of the earnings, which is a critical driver for insurers.
• Currency Impact: While the average yen/dollar rate is noted (156.87), the specific translation impact on the *full* year outlook is not detailed in the provided snippets.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: Japan sales up 25.5% YoY with 35% pretax margin; Net earnings recovered to $1.0B from $29M YoY; $1.3B returned to shareholders in Q1 with 105.3M shares remaining for buyback. Key risks: Coil remains in forming state with sub-threshold ATR (1.9%) indicating slow momentum; Price is 1.7% below breakout entry; FX volatility (Yen at 156.87) could impact reported earnings. Sizing hint: Position size should reflect the partial setup readiness (forming coil) and sub-threshold volatility; avoid full sizing until breakout confirmation. Expected path: Management expects continued sales momentum in Japan driven by new products and U.S. group voluntary growth; capital return program likely to continue. Expected horizon: 3 to 6 months for setup confirmation and fundamental thesis to play out.